63 results about "Castration" patented technology

This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer and methods of increasing overall survival thereof.

The present invention belongs to the field of biomedicine technology, and relates to the application of the Lnc-FLJ gene in the treatment of castration-resistant prostate cancer. The application of the Lnc-FLJ gene inhibitor in the preparation of prostate cancer drugs. The present invention discovered for the first time that Lnc-FLJ can inhibit the proliferation and autophagy of castration-resistant prostate cancer. Lnc-FLJ is more highly expressed in castration-resistant prostate cancer cells and prostate cancer tissues with higher malignancy. Inhibiting Lnc-FLJ can inhibit the occurrence and development of castration-resistant prostate cancer. The preparation of Lnc-FLJ small molecule inhibitor shRNA is used to treat castration-resistant prostate cancer and cancer insensitive to enzalutamide, thereby inhibiting the AR signaling pathway. The present invention provides new ideas for further studying the pathogenesis of castration-resistant prostate cancer and the function of the Lnc-FLJ gene, and provides a new direction for the development of castration-resistant prostate cancer drugs.

The invention provides a dalotamide monophosphate compound shown as a formula I or a pharmaceutically acceptable salt thereof, and n is an integer of 1-3, preferably an integer of 1-2. The compound provided by the invention can be used for preparing medicines for treating adult patients with non-metastatic castration-resistant prostate cancer with high metastasis risk.

The invention belongs to the technical field of cancer treatment, and discloses a method for inhibiting castration-resistant prostate cancer proliferation and metastasis by promoting collagen degradation through targeting ADAMTS1. According to the method, ADAMTS1 is determined to be a mechanism key point for linking epigenetic reprogramming with biomechanical microenvironment destruction. The ADAMTS1 is reactivated to degrade a collagen-rich matrix, the FAK / MAPK mechanical transduction signaling pathway is inhibited, and the epithelial-mesenchymal transition (EMT) is reversed. The strategy not only achieves more than 90% of tumor inhibition effect, but also exhausts immunosuppressive macrophages and regulatory T cells to reverse immunosuppression by enhancing toxic CD8 + T cell infiltration. The research determines that epigenetic-ECM coevolution is a symbolic feature of CRPC, and provides a reasonably designed combination therapy for treating castration-resistant prostate cancer.

Methods of treating non-metastatic castration-resistant prostate cancer in a subject having severe liver damage are provided.SOLUTION: Provided are methods of treating non-metastatic castration-resistant prostate cancer in a subject with severe hepatic impairment with an androgen receptor inhibitor comprising 4 - [7 - (6-cyano-5-trifluoromethylpyridin-3-yl) - 8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl] - 2-fluoro-N-methylbenzamide (apalutamide).SELECTED DRAWING: None

This is a method for treating prostate cancer. Specifically, it involves the use of the compound shown in Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a drug for treating metastatic castration-resistant prostate cancer. [Formula 1] JPEG2026521901000005.jpg32155

The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509 and HPMCAS in a suitable solvent.

The invention relates to the technical field of biological medicine, and particularly discloses application of nefenavir. Nefinavir is used for preparing a medicine for treating or preventing castration-resistant prostate cancer, and the medicine can specifically up-regulate expression of DHCR7, induce DNA damage of tumor cells and activate a cell cycle arrest pathway mediated by periodic protein of the cells so as to inhibit key biological processes such as proliferation of the tumor cells, cholesterol metabolism and the like; especially, formation and amplification of multinuclear giant cells in castration-resistant prostate cancer can be effectively inhibited by up-regulating expression of DHCR7, so that malignant progression of multinuclear giant cell mediated tumors and treatment of drug resistance are blocked. Finally, the castration-resistant prostate cancer is prevented and treated, and the technical bottlenecks that an existing castration-resistant prostate cancer treatment means is limited in curative effect, and the drug resistance and metastasis capability mediated by multinuclear giant cells are difficult to inhibit in a targeted manner are solved.

Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide.

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.

The invention belongs to the technical field of tumor resistance, and particularly relates to application of Se-coated SiO2-DTX in preparation of a product for treating prostate cancer or castration-resistant prostate cancer. The invention relates to an application of a tyrosine phosphorylation inhibitor or / and cPAP (c-Phosphorylation Inhibitor) for preventing or treating prostatic cancer or castration-resistant prostatic cancer, wherein the tyrosine phosphorylation inhibitor comprises at least one of Y < 279 >, Y < 357 > and Y < 488 >, and the tyrosine phosphorylation inhibitor can be used for preventing or treating prostatic cancer or castration-resistant prostatic cancer. According to the invention, Se-coated SiO2 and docetaxel are combined for use, so that not only can the direct anticancer effect of selenium in Se-coated SiO2 be played, but also the killing effect of the chemotherapeutic drug docetaxel on cancer cells can be improved, and the application has important clinical significance.

The present invention relates to: a composition for treating castration-resistant prostate cancer, comprising quassinoids; and a method for treating castration-resistant prostate cancer by using same.

The present invention relates to methods for predicting the progression of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC), in an individual. The invention employs gene expression profiling combined with predictive modeling to assess the likelihood of overall survival and biochemical recurrence following treatment.

This document provides methods and materials for treating cancer (e.g., prostate cancer). For example, methods for using one or more agents that can regulate splicing of a nucleic acid (e.g., a precursor-messenger ribonucleic acid (pre-mRNA)) encoding one or more androgen receptor (AR) polypeptides to treat a mammal having prostate cancer (e.g., castration-resistant prostate cancer (CRPC)) are provided.

The present disclosure relates to methods of treating prostate cancer, including prostate cancer comprising at least one somatic AR tumor mutation, in a subject, , for example, metastatic prostate cancer, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, progressive metastatic castration-resistant prostate cancer, castration-sensitive prostate cancer, metastatic castration-sensitive prostate cancer, prostate cancer that has not been treated with a novel hormone agent (NHA), metastatic prostate cancer that has not been treated with NHA; the present invention relates to methods of treating a castration-resistant prostate cancer, a castration-sensitive prostate cancer, a metastatic castration-resistant prostate cancer, and a metastatic castration-sensitive prostate cancer, where the methods comprise administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof. And a # imgabs0 # compound A.

This document provides methods and materials for treating cancer (e.g., prostate cancer). For example, methods for using one or more agents that can regulate splicing of a nucleic acid (e.g., a precursor-messenger ribonucleic acid (pre-mRNA)) encoding one or more androgen receptor (AR) polypeptides to treat a mammal having prostate cancer (e.g., castration-resistant prostate cancer (CRPC)) are provided.

The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509 and HPMCAS in a suitable solvent.

This disclosure relates to methods of treating prostate cancer in a subject. This disclosure more specifically relates to methods for treating prostate cancer, such as metastatic castration-resistant prostate cancer, by administering to the subject olaparib and abiraterone acetate or a salt thereof.

Methods are provided for insect control, including controlling fly maggot disease, in an animal by securing to the animal an elastic band impregnated or containing therein an insecticide, an insect repellant, lidocaine, or any combination thereof. The insect control may be dual mode control, and may be directed against existing or impending open wounds, including open wounds caused by castration, tagging, umbilical ligation, or chamfering of animals. Also provided are methods for castration, tail cutting, umbilical cord ligation, or chamfering of animals while insect control. Elastic bands for insect control and methods of making such elastic bands are also provided.

The application discloses a compound based on a PROTAC strategy and a preparation method, a pharmaceutical composition and application thereof, discloses a compound with AR / AR-V7 protein degradation activity and a preparation method, a pharmaceutical composition and application thereof. The structure of the compound is as shown in the formula I. The compound can effectively degrade AR / AR-V7 proteins in vivo and in vitro, has a significant antitumor effect, has no obvious toxic side effects, and can be used for treating castration-resistant prostate cancer. The preparation method of the compound is simple and easy to operate, and is beneficial to structural expansion.

There is provided methods for insect control, including controlling myiasis, in animals by affixing to the animal an elastomeric band having infused or contained within an insecticide, an insect repellant, lidocaine, or any combination thereof. The insect control may be a dual-mode control and may be in respect of existing or impending open wounds, including open wounds caused by castration, tail docking, umbilical cord ligation, or dehorning of an animal. There is also provided methods for castration, docking, umbilical cord ligation, or dehorning of an animal with concurrent insect control. Also provided are elastomeric bands for insect control and methods for preparing such elastomeric bands.

The present disclosure discloses application of PRDX5 and GPX4 genes in preparation of drugs for castration-resistant prostate cancer and belongs to the technical field of biological medicines. The present disclosure proposes that silencing or interfering with the expression of the PRDX5 and / or GPX4 genes can be used in the treatment or adjuvant treatment of castration-resistant prostate cancer. The present disclosure proposes for the first time a new strategy for preparing the drugs for the treatment of CRPC using siRNA in combination with an androgen receptor antagonist. The pharmaceutical composition comprising siRNA in combination with an androgen receptor antagonist according to the present disclosure can be used for the treatment of castration-resistant prostate cancer and significantly improves the inhibitory effect of enzalutamide on castration-resistant prostate cancer, which provides the basis for the design and clinical application of nucleic acid drugs with important clinical therapeutic significance.

The present invention relates to the technical field of biology, and particularly to an animal castration method. The present invention provides a non-surgical animal castration method, comprising administering a GnRH-I-AP205 virus-like particle subunit vaccine to an animal. The method is good in safety and non-irritant, does not cause anaphylaxis, and is still safe under overdosage. Moreover, the required dosage is small, and 0.25 ml per animal is able to take effect.

Described herein are radiopharmaceuticals for the treatment of PSMA-expressing cancers, and methods and / or uses of such compounds for the treatment of PSMA-expressing cancers, such as, for example, metastatic castration-resistant prostate cancer.

There is provided methods for insect control, including controlling myiasis, in animals by affixing to the animal an elastomeric band having infused or contained within an insecticide, an insect repellent, lidocaine, or any combination thereof. The insect control may be a dual-mode control and may be in respect of existing or impending open wounds, including open wounds caused by castration, tail docking, umbilical cord ligation, or dehorning of an animal. There is also provided methods for castration, docking, umbilical cord ligation, or dehorning of an animal with concurrent insect control. Also provided are elastomeric bands for insect control and methods for preparing such elastomeric bands.

The present invention relates to a dosage regimen of a tevirelix-TFA composition for the treatment of prostate cancer. The dosing regimen comprises a loading dose of 360 mg SC and 180 mg IM tevirelix-TFA composition, and a low maintenance dose (360 mg SC) of the tevirelix-TFA composition once every six weeks starting from the 28th day. Thus, the dosing regimen according to the present invention provides an improved dosing regimen in which a castration rate of > = 95% is obtained over a treatment period of 52 weeks, and less side effects and adverse events, thereby providing an optimized response / side effect relationship.

1. The name of the product of this design: castration knife. 2. Purpose of this design product: This design product is a medical device used for performing surgery on animals. 3. The design key point of this appearance design product lies in the shape. 4. The picture or photo that best illustrates the design points: Stereoscopic diagram 1.

A method for castration of animals. A non-surgical method for castration of animals which includes administering GnRH-I-AP205 virus-like particle subunit vaccine to animals. The required dose is very small, and 0.25 ml / animal will work.

The present disclosure relates to a method of treating prostate cancer, including prostate cancer comprising at least one somatic AR tumor mutation in a subject, e.g., metastatic prostate cancer, castration-resistant prostate cancer, metastatic castration-resistant prostate cancer, progressive metastatic castration-resistant prostate cancer, castration-sensitive prostate cancer, metastatic castration-sensitive prostate cancer, novel hormonal agent (NHA)-naive prostate cancer, NHA-naive metastatic prostate cancer, NHA-naive castration-resistant prostate cancer, NHA-naive castration-sensitive prostate cancer, NHA-naive metastatic castration-resistant prostate cancer, and NHA-naive metastatic castration-sensitive prostate cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof. JPEG2026500894000245.jpg50170